P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 12.42 CNY -1.04% Market Closed
Market Cap: 4.3B CNY
Pulike Biological Engineering Inc
/
Income Statement
/
Revenue

Pulike Biological Engineering Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pulike Biological Engineering Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
P
Pulike Biological Engineering Inc
SSE:603566
Revenue
¥1.1B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
¥10.1B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Revenue
¥10.9B
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
¥26B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
¥39.3B
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
8%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Revenue
¥2.1B
CAGR 3-Years
16%
CAGR 5-Years
10%
CAGR 10-Years
N/A

Pulike Biological Engineering Inc
Glance View

Market Cap
4.3B CNY
Industry
Pharmaceuticals

Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Intrinsic Value
17.35 CNY
Undervaluation 28%
Intrinsic Value
Price
P
What is Intrinsic Value?

See Also

What is Pulike Biological Engineering Inc's Revenue?
Revenue
1.1B CNY

Based on the financial report for Sep 30, 2024, Pulike Biological Engineering Inc's Revenue amounts to 1.1B CNY.

What is Pulike Biological Engineering Inc's Revenue growth rate?
Revenue CAGR 5Y
11%

Over the last year, the Revenue growth was -18%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.